stars 1 stars 2 stars 3

Advancing Biomedical Solutions Revatis is dedicated to driving progress in biomedical technology, offering practical solutions that address real-world challenges. With a focus on research and development, we're committed to delivering innovations that make a meaningful impact on healthcare. Our patented technology for obtaining multipotent stem cells from muscle micro-biopsies represents a significant breakthrough in regenerative medicine. These stem cells show promise in addressing various medical issues, from tissue repair to immune modulation, in both veterinary and human applications. But our work doesn't stop there. We're constantly exploring new avenues, including extracellular vesicle production, 3D cell culture using platelet lysates, and proprietary enzymatic reagents for cell release. These efforts are aimed at developing practical, effective solutions that improve patient outcomes. Collaboration is central to our approach. By partnering with leading institutions and experts, we leverage collective expertise to accelerate the development and adoption of innovative therapies. Join us in our mission to advance healthcare. Explore the possibilities with Revatis, where innovation meets practicality.

Revatis Questions

The Revatis annual revenue was $600000 in 2026.

Didier Serteyn is the Managing Director of Revatis.

10 people are employed at Revatis.

Revatis is based in Aye, Wallonia.

The NAICS codes for Revatis are [54171, 541, 541711, 54, 5417].

The SIC codes for Revatis are [28, 283, 80].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users